DaVita (DVA) Stock Valuation Check After Strong Year-To-Date Rally

DaVita stock overview after recent performance shift

DaVita (DVA) has drawn investor attention after a strong run, with the stock up 78% year to date and about 48% over the past year, compared with roughly 35% over the past 3 months.

Those headline moves sit alongside reported revenue of US$13.84b and net income of US$756.42m. The business is anchored primarily in U.S. dialysis patient services and related kidney care offerings, along with ancillary and international operations.

See our latest analysis for DaVita.

Recent trading has been strong, with a 2.66% 1 day share price return and a 35.24% 90 day share price return. The 1 year total shareholder return of 48.40% points to sustained momentum rather than a short term spike.

If DaVita’s move has you thinking about what else could be gaining traction in healthcare, it may be worth scanning 40 healthcare AI stocks

With DaVita now trading around US$203.83 after a strong run and sitting at a reported intrinsic premium, the key question is whether the stock still offers value or if the market is already fully pricing in its prospects.

Most Popular Narrative: 5.2% Overvalued

DaVita’s last close of $203.83 sits above the most followed fair value estimate of $193.71, which is built on a detailed discounted cash flow model using an 8.11% discount rate.

Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes, which management expects to support margin improvement even in periods of flat or negative volume growth. The company’s disciplined cost management and improved labor productivity have led to lower patient care costs per treatment, and with higher employee retention and training efficiencies expected to continue, this trend provides ongoing tailwinds for net margins.

Read the complete narrative.

Curious how a stock priced above its fair value can still be backed by detailed forecasts for revenue, margins and earnings per share over several years? The core of this narrative is a specific path for treatment volumes, profitability and future valuation multiples that have to hold together for the model to work. The interesting part is which assumptions carry the most weight in getting from today’s earnings base to that future earnings power.

Result: Fair Value of $193.71 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, elevated patient mortality and reimbursement increases that trail cost inflation could still pressure treatment volumes and margins, challenging the fair value narrative.

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.

Another View on DaVita’s Valuation

The DCF based fair value of $140.37 suggests DaVita is trading at a premium, yet the current P/E of 17.3x sits below the US Healthcare average of 22.7x, the peer average of 35.9x, and a fair ratio of 24.5x. This raises a key question: is the bigger risk overpaying based on cash flows, or underestimating what the market might be willing to pay for earnings?

To see how this cash flow view is built and to stress test the inputs against your own assumptions, Look into how the SWS DCF model arrives at its fair value.

Next Steps

If the mixed signals around DaVita’s valuation and outlook feel hard to pin down, look at the underlying data now and decide what matters most to you. Then round out your view by weighing the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If DaVita is already on your radar, now is the time to broaden your watchlist and uncover a few more stocks that could sharpen your portfolio.

• Target resilience by scanning 67 resilient stocks with low risk scores that focus on companies with lower risk scores and more stable profiles.
• Hunt for quality at a potential discount through 46 high quality undervalued stocks that highlight stocks combining solid fundamentals with appealing pricing.
• Strengthen your core holdings by reviewing solid balance sheet and fundamentals stocks screener (47 results) featuring companies with firmer financial footing and supportable fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com